

ASX RELEASE

13 November 2019

KAZIA ANNUAL GENERAL MEETING RESULTS

Sydney, 13 November 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals are attached.

Kazia Chairman, Iain Ross, commented “we are grateful to once again have the comprehensive support of our shareholders during this exciting chapter in the company’s development. Almost 40% of the issued share capital was voted, and support of the resolutions exceeded 95% for all resolutions, providing a powerful endorsement of the company’s strategy and potential. In less than two weeks, we expect to announce initial interim data from the ongoing phase II study of GDC-0084, and this will mark an important inflection point as we head into 2020.”

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and further data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Interim data was presented at the ESMO Congress in September 2019, and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Kazia Therapeutics Limited
2019 Annual General Meeting
Wednesday, 13 November 2019
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	26,502,358 97.56%	373,826 1.37%	291,229 1.07%	575,965	27,098,515 98.64%	373,826 1.36%	575,965	Carried
2 Re-election of Steven Coffey	Ordinary	27,771,657 98.16%	229,649 0.81%	291,229 1.03%	358,611	28,367,814 99.20%	229,649 0.80%	358,611	Carried
3 Approval of grant of Options to Dr James Garner	Ordinary	25,798,206 94.80%	1,138,345 4.19%	275,854 1.01%	650,973	26,344,060 95.85%	1,140,768 4.15%	683,478	Carried
4 Placement capacity under Listing Rule 7.1A	Special	27,527,737 97.81%	325,821 1.16%	291,229 1.03%	506,359	28,121,471 98.85%	328,244 1.15%	506,359	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.